Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved?
El-Cheikh J, Crocchiolo R, Boher JM, Fürst S, Stoppa AM, Faucher C, Castagna L, Granata A, Oudin C, De Colella JM, Coso D, Bouabdallah R, Mohty M, Blaise D. El-Cheikh J, et al. Among authors: faucher c. Leuk Lymphoma. 2012 Aug;53(8):1630-2. doi: 10.3109/10428194.2012.656630. Epub 2012 Feb 13. Leuk Lymphoma. 2012. PMID: 22239670 No abstract available.
Poor autologous mobilization status does not impact on hematological recovery but affects outcome after allogeneic stem cell transplant for lymphoma and myeloma.
Crocchiolo R, Chabannon C, El-Cheikh J, Esterni B, Lemarié C, Fürst S, Castagna L, Bouabdallah R, Ladaique P, Coso D, Schiano JM, Stoppa AM, Rey J, Ivanov V, Aurran T, Faucher C, Blaise D, Calmels B. Crocchiolo R, et al. Among authors: faucher c. Leuk Lymphoma. 2013 Feb;54(2):417-20. doi: 10.3109/10428194.2012.702901. Epub 2012 Jul 9. Leuk Lymphoma. 2013. PMID: 22702654 No abstract available.
Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high-risk multiple myeloma.
El-Cheikh J, Crocchiolo R, Boher JM, Furst S, Stoppa AM, Ladaique P, Faucher C, Calmels B, Castagna L, Lemarie C, De Colella JM, Coso D, Bouabdallah R, Chabannon C, Blaise D. El-Cheikh J, et al. Among authors: faucher c. Eur J Haematol. 2012 Jun;88(6):497-503. doi: 10.1111/j.1600-0609.2012.01777.x. Epub 2012 Apr 4. Eur J Haematol. 2012. PMID: 22385049
National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Saillard C, Crocchiolo R, Furst S, El-Cheikh J, Castagna L, Signori A, Oudin C, Faucher C, Lemarie C, Chabannon C, Granata A, Blaise D. Saillard C, et al. Among authors: faucher c. Leuk Lymphoma. 2014 May;55(5):1106-12. doi: 10.3109/10428194.2013.820285. Epub 2014 Feb 4. Leuk Lymphoma. 2014. PMID: 23822538
The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia.
Wanquet A, Crocchiolo R, Furst S, Granata A, Faucher C, Devillier R, Harbi S, Lemarie C, Calmels B, Vey N, Weiller PJ, Chabannon C, Castagna L, Blaise D, El-Cheikh J. Wanquet A, et al. Among authors: faucher c. Leuk Lymphoma. 2016 Oct;57(10):2315-20. doi: 10.3109/10428194.2016.1146948. Epub 2016 Feb 17. Leuk Lymphoma. 2016. PMID: 26885686
Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J, Crocchiolo R, Furst S, Stoppa AM, Ladaique P, Faucher C, Calmels B, Lemarie C, De Colella JM, Granata A, Coso D, Bouabdallah R, Chabannon C, Blaise D. El-Cheikh J, et al. Among authors: faucher c. Am J Hematol. 2013 May;88(5):370-4. doi: 10.1002/ajh.23412. Epub 2013 Mar 5. Am J Hematol. 2013. PMID: 23460414 Free article.
High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
El-Cheikh J, Michallet M, Nagler A, de Lavallade H, Nicolini FE, Shimoni A, Faucher C, Sobh M, Revesz D, Hardan I, Fürst S, Blaise D, Mohty M. El-Cheikh J, et al. Among authors: faucher c. Haematologica. 2008 Mar;93(3):455-8. doi: 10.3324/haematol.12184. Epub 2008 Feb 20. Haematologica. 2008. PMID: 18287132 Free article.
Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma.
El-Cheikh J, Crocchiolo R, Furst S, Ladaique P, Castagna L, Faucher C, Granata A, Oudin C, Lemarie C, Calmels B, Stoppa AM, Schiano De Colella JM, Duran S, Chabannon C, Blaise D. El-Cheikh J, et al. Among authors: faucher c. Exp Hematol. 2012 Jul;40(7):521-7. doi: 10.1016/j.exphem.2012.02.009. Epub 2012 Mar 23. Exp Hematol. 2012. PMID: 22446605 Free article. Clinical Trial.
239 results